Valion Bio Inc
tivichealth.comWhat Do They Do?
Develops Entolimod and Entolasta for acute radiation syndrome and oncology-related conditions, and provides biomanufacturing development and manufacturing services to biotechnology companies.
10-K for FY2025, filed Mar 30, 2026Tivic™ Health Systems, Inc. is a late-stage biopharmaceutical company whose lead program is Entolimod™. Entolimod is a recombinant TLR5…View ↗
The Company is now focused on (1) advancing Entolimod and its next generation compound Entolasta™ through regulatory approval for acute…View ↗
Velocity Bioworks, Inc. offers biomanufacturing development work, analytic support, and CGMP manufacturing capability. While we are in the…View ↗
How Do They Make Money?
For product sales, customers buy directly or through resellers, and sales are recorded when the products ship.
10-K for FY2025, filed Mar 30, 2026The Company has sold its products through direct sales and resellers. Revenue is recognized when control of the promised goods is…View ↗
$780K
-
10-K for FY2024, filed Mar 21, 2025
$780K ↗
Who Are Their Customers?
Velocity Bioworks provides development and manufacturing services to third-party biotechnology companies.
8-K, filed Aug 27, 2026Valion Bio’s wholly owned subsidiary, Velocity Bioworks®, is a biologics contract development and manufacturing organization providing…View ↗
Do Revenues Turn Into Profits?
No. It lost $5.7M in FY2024.
10-K for FY2025, filed Mar 30, 2026
−$4.5MView ↗
10-K for FY2025, filed Mar 30, 2026
−$5.7MView ↗
10-K for FY2025, filed Mar 30, 2026
−$5.7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$7.1MView ↗
- ▲ +268% (Loss)
- vs −$1.9M in Q2 FY2025
-
Sep 1, 2026
CEO Michael K. Handley departed; Lisa Wolf became President and COO
Sources
8-K, filed Sep 1, 2026
The Company’s Board of Directors has unanimously appointed Lisa Wolf to the expanded roles of President and Chief Operating Officer…View ↗
From devices to drug development
The older report centers on non-invasive bioelectronic medicine and ClearUP; the latest describes a pivot to a focused biopharma company developing Entolimod and Entolasta, while ending consumer-health operations.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026
Loading...
